Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more.

Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

The book is a comprehensive and in-depth overview of the latest developments in gene and cellular immunotherapies The content is divided into six cohesive sections, CAR-T, TCR-T, TIL, Viral CTL, NK Cell, and T/NK Cell Engagers This book will feature chapters written by a collection of recognized and up-and-coming researchers in the field

Autorentext
Armin Ghobadi is an Associate Professor in the Division of Oncology and clinical director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine in St. Louis, and a member of the Alvin J. Siteman Cancer Center. He earned his Medical Diploma at Iran University of Medical Sciences and Health Services School of Medicine in Tehran. Ghobadi's post graduate training has been at the University of Texas Southwestern Medical School in Dallas, TX, the MD Anderson Cancer Center in Houston, TX and Washington University School of Medicine in St. Louis. Currently his research focuses on cellular therapy for hematologic malignancies, hematopoietic stem cell transplantation, and genome sequencing

John F. DiPersio is the Deputy Director of Alvin J. Siteman Cancer Center, Samuel J. Goldman Endowed Professor of Oncology, Chief of the Division of Oncology, and director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine inSt. Louis. DiPersio earned a BA in Biology at Williams College in Williamstown, MA and a Ph.D./MD in Microbiology at the University of Rochester, Rochester, NY. Currently, his research focuses on hematopoietic stem cell mobilization, murine models of graft-versus host disease and graft-versus leukemia, leukemia genomics and targeted cellular therapies for the treatment of leukemias.

Inhalt

The History of Cellular Therapies.- Basics of Immunity.- Biology of CAR T cells.- Cell types used for CAR generation.- Combination therapeutics with CART cell therapy.- Safety switches used for cellular therapies.- Off-the-shelf CAR-T.- Manufacturing of CAR-T Cells: the Assembly Line.- Navigating Regulations in Gene and Cell Immunotherapy .- Bringing CAR-T to the Clinic.- CAR T-Cell Complications.- Mechanisms of Resistance and Relapse after CAR T cell therapy.- Tumor infiltrating lymphocytes (TIL): from bench to bedside.- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic.- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside.- Biology of NK cells and NK cells in clinic.- Biology and Clinical Evaluation of T/NK Cell Engagers.- Roadmap for Starting an Outpatient Cellular Therapy Program.- Index.